Patient Experiences with Psoriatic Disease in the USA: Results from the Psoriasis and Beyond Global Study.

Background: Psoriatic disease (PsD) is a chronic, multisystem, inflammatory disorder encompassing psoriasis, psoriatic arthritis (PsA), and their associated comorbidities.

Objective: The aim of this subanalysis of the global "Psoriasis and Beyond" study was to evaluate patients' experiences of living with PsD in the USA.

Methods: The study included a cross-sectional, quantitative, 25-min online survey of adults with self-reported, healthcare professional-diagnosed, moderate-to-severe psoriasis, with or without PsA.

SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement.

Background: Patients with psoriasis affecting a low percentage of their body surface area (BSA) are underrepresented in clinical studies and may face substantial disease burden if high-impact sites are affected.

Objectives: SPECTREM is a Phase 3b, randomized, placebo-controlled study evaluating guselkumab efficacy and safety in participants with low BSA (2%-15%), moderate (Investigator's Global Assessment [IGA]=3) plaque psoriasis involving ≥1 high-impact site (scalp, face, genitals, intertriginous areas).

Methods: Eligible participants were randomized 2:1 to receive guselkumab 100 mg or placebo at Week 0 and Week 4, then every 8 weeks.

Report of the IDEOM Meeting Adjacent to the GRAPPA 2024 Annual Meeting.

The International Dermatology Outcome Measures (IDEOM) organization presented updates on its patient-reported outcome measures (PROMs) for psoriasis (PsO), psoriatic arthritis (PsA), and other immune-mediated skin diseases at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting. The Hidradenitis Suppurativa working group reported on the IDEOM Musculoskeletal Questionnaire (MSK-Q), a PROM for MSK manifestations of psoriatic disease. Advances in PsA screening included integrating the Psoriasis Epidemiology Screening Tool (PEST) and 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaires into the Epic electronic health record system to streamline detection and management of emerging PsA cases.

Hot Topics: Exploring Artificial Intelligence and Inflammatory Memory in the Management of Psoriatic Diseases.

The "hot topics" session of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting and trainee symposium explored the integration of artificial intelligence (AI) in managing psoriatic diseases (PsD) and the underlying mechanisms of inflammatory memory that drive recurrence in psoriasis and psoriatic arthritis. Drs. April Armstrong and Denis Poddubnyy discussed the transformative role of AI in enhancing diagnostic accuracy, assessing disease severity, and predicting treatment responses, particularly through deep learning models such as convolutional neural networks.

Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis.

Background: There is an unmet need for oral psoriasis medications with improved efficacy and safety.

Objective: We evaluated the efficacy and safety of oral ME3183, a novel phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis.

Methods: This was a randomized, double-blind, placebo-controlled study with a 16-week double-blind treatment period.

Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials.

Introduction: Patients with atopic dermatitis (AD) and skin of color have heterogeneous presentations and treatment outcomes, however, they are underrepresented in trials. In the ADORING 1 and 2 phase 3, 8-week randomized trials, tapinarof cream 1% once daily (QD) demonstrated superior efficacy versus vehicle in adults and children down to age 2 years with AD. These analyses evaluate efficacy of tapinarof cream 1% QD stratified by race and Fitzpatrick skin type.

Tirbanibulin 1% Ointment: Clinical Trial and Real-World Evidence on Efficacy, Tolerability, Safety, and Patient-Reported Outcomes.

Actinic keratosis (AK) is a skin lesion that arises due to chronic sun exposure. Treatment of all AKs is recommended due to their risk of progressing to squamous cell carcinomas (SCCs). Many field-directed treatments for AKs involve burdensome treatment duration and frequency, compromising treatment compliance.

Tirbanibulin 1% Ointment: The Mechanism of Action of a Novel Topical Therapy for Actinic Keratosis.

Actinic keratosis (AK) is a common, precancerous skin lesion that may progress to squamous cell carcinoma (SCC). Traditional topical therapies for AKs often require long treatment durations. These therapies may also cause significant local skin reactions that can reduce patient adherence.

The Epidemiology of Atopic Dermatitis among Adults and Adolescents with Alopecia Areata in the United States.

This study evaluated the prevalence, incidence, and relative risk of comorbid atopic dermatitis (AD) among patients with alopecia areata (AA) using data from the Merative MarketScan Research Databases. Eligible patients had ≥1 inpatient or ≥2 outpatient claims for AA between January 1, 2017 and October 31, 2023; were aged ≥12 years; and were continuously enrolled during the ≥5-year baseline period through the 6-month follow-up period; index date was the earliest date of AA diagnosis. AD prevalence (%) and incidence (cases per 1000 person-years) among patients with AA are reported and stratified by disease severity; a subgroup analysis was performed among adolescents (aged 12-17 years).

Psoriasis.

Plaque psoriasis is a chronic, immune-mediated inflammatory skin disease that has considerable effects on patients' physical, psychological and social well-being. It is strongly influenced by genetic predisposition, with HLA-C*06:02 showing the strongest association, particularly in those with early-onset disease. Additional susceptibility loci, including IL23A, IL12B and IL17RA, are linked to dysregulation of the IL-23-T helper 17 axis, which contributes to chronic inflammation and keratinocyte hyperproliferation.

Do female patients see their physicians differently? A population-based study evaluating perception of physician communication by patients with hidradenitis suppurativa.

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition that causes painful abscesses, nodules, fistulae, and fibrotic scars. Management of HS requires strong physician-patient communication; however, it is not known if male and female HS patients perceive physician communication differently. This study aimed to determine if patient-perceived quality of physician communication differs between male and female HS patients.

Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation.

Importance: Defining on-treatment remission in plaque psoriasis is important for benchmarking patient responses to therapies. This also helps to facilitate shared understanding, align treatment expectations, and enable more effective psoriasis management.

Objective: To establish a consensus-based definition of on-treatment remission for plaque psoriasis through a multistage Delphi initiative.

Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry.

Introduction: Psoriasis body surface area (BSA) of 10% or more has been a major criterion for determining systemic therapy eligibility. However, patients with BSA < 10% and even ≤ 3% may have high disease burden and difficulties accessing biologics. To assess psoriasis burden among patients with BSA ≤ 10%, this study characterized patient-reported outcomes (PROs) across BSA categories among systemic treatment-naïve patients initiating biologic therapy.

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms.

Introduction: For patients with psoriasis, psoriatic arthritis can be a painful comorbid condition that is often undiagnosed. It is therefore essential that more research is done to understand which treatments for psoriasis relieve both dermatologic and joint symptoms. This analysis aimed to compare the effects of deucravacitinib vs.

Comparing antibiotic prescribing patterns for hidradenitis suppurativa between the emergency department and ambulatory care setting.

Background: Oral antibiotics are a mainstay of treatment for hidradenitis suppurativa (HS), primarily due to their anti-inflammatory and anti-microbial properties. There is a paucity of literature comparing how antibiotic prescribing patterns for HS patients differ between the emergency department (ED) and ambulatory care settings.

Objective: This study aims to compare antibiotic prescribing patterns for HS patients in the ED versus ambulatory care setting.

Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.

Background: Ruxolitinib (Janus kinase 1 and Janus kinase 2 inhibitor) cream demonstrated efficacy and safety in adolescents and adults with mild-to-moderate atopic dermatitis (AD).

Objective: To evaluate 8-week efficacy and safety of ruxolitinib cream in children with mild-to-moderate AD.

Methods: This phase 3 study (TRuE-AD3; NCT04921969) enrolled children aged 2-11 years with an Investigator's Global Assessment (IGA) score of 2 or 3 and 3% to 20% affected body surface area.

Efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis.

Background: The age of psoriasis onset is bimodally distributed with distinct peaks at < 40 (early onset) and ≥ 40 years (late onset) of age. Although the age of psoriasis onset is associated with distinct disease profiles, few well-controlled studies have reported the efficacy of biologics in patients with early- vs. late-onset disease.

Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes.

Introduction: This randomized, prospective study (MATCH) was designed to assess the clinical utility of a machine learning-based tool (Mind.Px) that predicts patient response to the biologic drug classes used in the management of psoriasis.

Methods: Patients with psoriasis who were biologic naïve or approaching a medication change owing to nonresponse were enrolled into the study (N = 210).

Emergency versus Outpatient Care for Pediatric Atopic Dermatitis: A Population-Based Study of Sociodemographic Factors and Health Care Utilization.

Objective: To examine sociodemographic differences in pediatric atopic dermatitis (AD) visits between emergency and outpatient settings.

Study Design: We used the National Hospital Ambulatory Medical Care Survey and National Ambulatory Medical Care Survey to identify emergency and outpatient visits for pediatric AD patients from 2009-2016 to 2018-2019.

Results: We identified 16 712 960 visits for pediatric AD (weighted).

Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials.

Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the USA and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. In POETYK PSO-1 and PSO-2, deucravacitinib was superior to placebo and apremilast and well tolerated in patients with plaque psoriasis. Patients who completed PSO-1/PSO-2 could enroll in the POETYK long-term extension (LTE) trial.

Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.

Background: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Objectives: To evaluate the safety and efficacy of deucravacitinib through 4 years in the Phase 3 POETYK PSO-1, PSO-2 and long-term extension (LTE) trials in psoriasis.

Methods: PSO-1 and PSO-2 (parent trials) randomized patients 1:2:1 to oral placebo, deucravacitinib 6 mg once daily (QD) or apremilast 30 mg twice daily.